Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 7,70 € (+606,42 %). Medianen er 8,36 € (+666,97 %).
| Køb |
2 |
| Behold |
1 |
| Sælg |
1 |
Nyheder Til nyhedsfeedet
Tvardi presents positive phase 1 data for STAT3 inhibitor TTI-109
Tvardi reports results from a phase 1 study of TTI-109, a phosphate prodrug of TTI-101: TTI-109 converts to TTI-101 within two hours and produces similar plasma levels at molar-equivalent doses. Twenty-one days of repeated dosing showed dose-proportional pharmacokinetics and TTI-101 concentrations above the IC50 for STAT3. Pharmacodynamic data document up to a 60% reduction in STAT3-driven immune cell populations; diarrhea was shorter with TTI-109 than with TTI-101. Tvardi plans to further develop TTI-109 for dermatological and gastrointestinal indications, pending IND approval and additional funding. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 0 | - |
| Bruttofortjeneste | 0 | 100,00 % |
| Nettoresultat | -5,66 mio. | 260,03 % |
| EBITDA | -5,79 mio. | 261,90 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 10,48 mio. € |
Antal aktier | 9,38 mio. |
Højeste/laveste i 52 uger | 38,40 € - 0,82 € |
| Udbytte | Nej |
Beta | 0,39 |
P/E (PE Ratio) | -0,46 |
PEG (PEG Ratio) | 0,01 |
K/I (PB Ratio) | 1,42 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
| Navn | Tvardi Therapeutics |
| CEO | Imran Alibhai |
| Medarbejdere | 12 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | TVRD |
